Medtronic (NYSE: MDT) reported Q4 EPS of $1.16, $0.06 better than the analyst estimate of $1.10. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.14 billion.

The company today provided its fiscal year 2016 revenue outlook and diluted cash earnings per share (EPS) guidance. In fiscal year 2016, the company expects full-year underlying operational revenue growth in the range of 4 to 6 percent, and in addition, the company expects an incremental 1.0 to 1.5 percent of full-year revenue growth due to the extra selling week in the first quarter of fiscal year 2016.

Medtronic sees FY2016 EPS of $4.30 - $4.40, versus the consensus of $4.45. The EPS outlook includes an expected $0.40 to $0.50 negative foreign currency impact based on current exchange rates. This foreign currency impact is $0.10 more negative than the amount previously estimated by the company in February.

For earnings history and earnings-related data on Medtronic (MDT) click here.